Please assess the completion status of the following clinical trial:

Trial Title: 3BNC117 and 10-1074 in HIV Uninfected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, age 18 to 65.~* Amenable to HIV risk reduction counseling and agrees to maintain behavior consistent with low risk of HIV exposure.~* If sexually active male or female, and participating in sexual activity that could lead to pregnancy, agrees to use two effective methods of contraception (i.e. condom with spermicide, diaphragm with spermicide, hormone-eluting IUD, hormone-based contraceptive with condom) for the duration of the study.~Exclusion Criteria:~* Confirmed HIV-1 or HIV-2 infection.~* History of immunodeficiency or autoimmune disease; use of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant by the trial physician within the last 6 months.~* Any clinically significant acute or chronic medical condition (such as autoimmune diseases) that in the opinion of the investigator would preclude participation.~* Within the 12 months prior to enrollment, the participant has a history of sexually transmitted infection.~* Chronic Hepatitis B or Hepatitis C infection.~* Laboratory abnormalities in the parameters listed:~* Absolute neutrophil count ≤ 2,000;~* Hemoglobin ≤ 12 gm/dL if female; ≤ 13.5 gm/dL if male;~* Platelet count ≤ 125,000;~* Alanine Aminotransferase (ALT) ≥ 1.25 x ULN; Aspartate Aminotransferase (AST) ≥ 1.25 x ULN;~* Alkaline phosphatase ≥ 1.5 x ULN~* Total bilirubin \> 1.0 x ULN;~* Creatinine ≥1.1 x ULN;~* Pregnancy or lactation.~* Any vaccination within 14 days prior to infusion~* Receipt of any experimental HIV vaccine in the past.~* History of severe reaction to a vaccine or drug infusion or history of severe allergic reactions.~* Participation in another clinical study of an investigational product currently or within past 12 weeks, or expected participation during this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Participants will be randomized in a 3:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion of 10-1074, each dosed at 10 mg/kg OR placebo (sterile saline), on day 0.
- Group 2 (Type: EXPERIMENTAL): Participants will be randomized in a 3:1 ratio to receive three intravenous infusions of 3BNC117 and three intravenous infusions of 10-1074, each dosed at 3 mg/kg OR placebo (sterile saline), on day 0, week 8, and week 16.
- Group 3 (Type: EXPERIMENTAL): Participants will be randomized in a 3:1 ratio to receive three intravenous infusions of 3BNC117 and three intravenous infusions of 10-1074, each dosed at 10 mg/kg OR placebo (sterile saline), on day 0, week 8, and week 16.

Based on this trial design, predict the completion outcome and termination type (if applicable).